iBio (IBIO) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
iBio (IBIO) has outperformed Talphera (TLPH) over the past year, gaining 5.7% versus a loss of 18.2%. Over five years, TLPH leads with a -94.7% price change compared with -99.8% for IBIO. iBio is the larger company by market cap ($56.3 million vs $56.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBIO | TLPH |
|---|---|---|
| Share price | $0.876 | $1.08 |
| Market cap | $56.33M | $56.06M |
| 1-day change | -4.78% | 0.00% |
| YTD return | -52.33% | -5.26% |
| 1-year return | +5.75% | -18.18% |
| 5-year return | -99.80% | -94.71% |
| EPS (TTM) | $-0.32 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $1.57 |
| 52-week low | $0.78 | $0.69 |
| Distance from 52-week high | -77.07% | -31.21% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +549.54% | +189.81% |
| Average volume | 727.93K | 238.38K |
| Shares outstanding | 64.31M | 51.91M |
| Employees | 23 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed TLPH by 23.9 percentage points over the past year.
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
IBIO vs TLPH FAQ
Which is bigger, iBio or Talphera?
iBio (IBIO) is larger, with a market capitalization of $56.33M compared with $56.06M for Talphera (TLPH).
Which stock has performed better over the past year, IBIO or TLPH?
IBIO returned +5.75% over the past 12 months, compared with -18.18% for TLPH (price return, excluding dividends). Past performance does not predict future results.
Are iBio and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.